2014
DOI: 10.5152/tjg.2014.3928
|View full text |Cite
|
Sign up to set email alerts
|

An unusual cause of duodenal obstruction: Mesenteric fibromatosis in a patient with type I Mayer-Rokitansky-Kuster-Hauser syndrome

Abstract: Patients with mesenteric fibromatosis (MF) are clinically asymptomatic, with little or no focal symptoms until later in their course, at which time they complain of pain, abdominal discomfort, constipation, vomiting, abdominal mass, weight loss, and symptoms due to organ compression. Generally, it occurs as an abdominal mass but may also present in many different ways. In some cases, trauma, previous abdominal surgery, and hormonal stimulation (such as estrogen) may play a role in onset of this neoplasm. Patie… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2017
2017
2018
2018

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 9 publications
0
1
0
Order By: Relevance
“…The tumor is mostly asymptomatic when it first emerges[ 1 - 5 ]. When it grows and starts to invade adjacent tissues or organs, however, it may produce signs and symptoms including abdominal discomfort, pain, palpable mass, intestinal obstruction, perforation, fistula, and inguinal hernia[ 1 - 3 ]. Depending on tumor size, growth pattern, and symptomatology, a staging model has been developed, which usually forms the basis for treatment planning[ 6 ].…”
Section: Introductionmentioning
confidence: 99%
“…The tumor is mostly asymptomatic when it first emerges[ 1 - 5 ]. When it grows and starts to invade adjacent tissues or organs, however, it may produce signs and symptoms including abdominal discomfort, pain, palpable mass, intestinal obstruction, perforation, fistula, and inguinal hernia[ 1 - 3 ]. Depending on tumor size, growth pattern, and symptomatology, a staging model has been developed, which usually forms the basis for treatment planning[ 6 ].…”
Section: Introductionmentioning
confidence: 99%